Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Hideo Gonda"'
Autor:
Hirotoshi Yasui, Kazuhide Sato, Yoshihiro Takeyama, Akira Ando, Toshio Kato, Hiroyuki Hashimoto, Yasutaka Fukui, Matsuyoshi Maeda, Hideo Gonda, Ryujiro Suzuki
Publikováno v:
Case Reports in Oncology, Vol 7, Iss 3, Pp 780-788 (2014)
Granulocyte colony-stimulating factor (G-CSF)-producing nonhematopoietic malignancies have been reported in various organs and are associated with a poor clinical outcome. Moreover, carcinoma of unknown primary site (CUP) is an uncommon malignancy th
Externí odkaz:
https://doaj.org/article/911d509112714cfc927acc9c973308de
Autor:
Hirotoshi Yasui, Kazuhide Sato, Yoshihiro Takeyama, Toshio Kato, Hiroyuki Hashimoto, Yasutaka Fukui, Nagashima Yoshihisa, Matsuyoshi Maeda, Hideo Gonda, Ryujiro Suzuki
Publikováno v:
Case Reports in Oncology, Vol 7, Iss 2, Pp 583-590 (2014)
About 3% of all cancer patients suffer from carcinoma of unknown primary site (CUP). In spite of its rarity, we will encounter them. While CUPs manifest a wide variety of clinical presentations, they have often resulted in poor prognosis. Although pl
Externí odkaz:
https://doaj.org/article/e70a57834c4e433487eddeea6933299b
Autor:
Kazuhide Sato, Yoshihiro Takeyama, Motoi Yoshihara, Toshio Kato, Hiroyuki Hashimoto, Yasutaka Fukui, Hideo Gonda, Ryujiro Suzuki
Publikováno v:
Case Reports in Oncology, Vol 5, Iss 3, Pp 546-553 (2012)
Based on the AVAPERL trial (36th ESMO 2011), CBDCA + pemetrexed + bevacizumab and its maintenance chemotherapy with pemetrexed + bevacizumab is a new promising regimen for the treatment of advanced non-small-cell lung adenocarcinoma. Herein, we repor
Externí odkaz:
https://doaj.org/article/97f2b58e1596480ca83f3f603297ed52
Autor:
Hirotoshi Yasui, Matsuyoshi Maeda, Hiroaki Nishihara, Ryujiro Suzuki, Hideo Gonda, Yoshihiro Takeyama, Kazuhide Sato
Publikováno v:
The American Journal of Case Reports
Patient: Male, 68 Final Diagnosis: Non-small cell lung cancer Symptoms: — Medication: — Clinical Procedure: TBLB • PET • OCT • fluorescence angiography Specialty: Oncology Objective: Challenging differential diagnosis Background: Visual dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9ad7bc1cb7146db487682f5bb19001e
https://doi.org/10.12659/ajcr.894600
https://doi.org/10.12659/ajcr.894600
Autor:
Yasutaka Fukui, Ryujiro Suzuki, Hirotoshi Yasui, Toshio Kato, Kazuhide Sato, Akira Ando, Hideo Gonda, Matsuyoshi Maeda, Hiroyuki Hashimoto, Yoshihiro Takeyama
Publikováno v:
Case Reports in Oncology, Vol 7, Iss 3, Pp 780-788 (2014)
Case Reports in Oncology
Case Reports in Oncology
Granulocyte colony-stimulating factor (G-CSF)-producing nonhematopoietic malignancies have been reported in various organs and are associated with a poor clinical outcome. Moreover, carcinoma of unknown primary site (CUP) is an uncommon malignancy th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90b3cbfe05804b9480b7e3a3f9d6530b
https://doi.org/10.1159/000369335
https://doi.org/10.1159/000369335
Autor:
Toshio Kato, Yasutaka Fukui, Ryujiro Suzuki, Nagashima Yoshihisa, Hirotoshi Yasui, Hideo Gonda, Yoshihiro Takeyama, Matsuyoshi Maeda, Kazuhide Sato, Hiroyuki Hashimoto
Publikováno v:
Case Reports in Oncology
Case Reports in Oncology, Vol 7, Iss 2, Pp 583-590 (2014)
Case Reports in Oncology, Vol 7, Iss 2, Pp 583-590 (2014)
About 3% of all cancer patients suffer from carcinoma of unknown primary site (CUP). In spite of its rarity, we will encounter them. While CUPs manifest a wide variety of clinical presentations, they have often resulted in poor prognosis. Although pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5eda091c9670bcdcd4e87d35bca5854c
http://europepmc.org/articles/PMC4178322
http://europepmc.org/articles/PMC4178322
Autor:
Kazuhide Sato, Yasutaka Fukui, Hiroyuki Hashimoto, Hideo Gonda, Toshio Kato, Ryujiro Suzuki, Yoshihiro Takeyama
Publikováno v:
Annals of Thoracic and Cardiovascular Surgery. 20:602-605
Primary tracheal tumors are uncommon, making up only 0.2% of all respiratory malignancies. Adenoid cystic carcinoma (ACC) is the most common tumor, accounting for about 30% of primary tracheal tumors. It is often difficult to manage these tumors surg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71d00932ff73031b9395ac08eef4a03c
https://doi.org/10.5761/atcs.cr.12.02156
https://doi.org/10.5761/atcs.cr.12.02156
Autor:
Yasutaka Fukui, Toshio Kato, Ryujiro Suzuki, Yoshihiro Takeyama, Motoi Yoshihara, Hiroyuki Hashimoto, Hideo Gonda, Kazuhide Sato
Publikováno v:
Case Reports in Oncology
Case Reports in Oncology, Vol 5, Iss 3, Pp 546-553 (2012)
Case Reports in Oncology, Vol 5, Iss 3, Pp 546-553 (2012)
Based on the AVAPERL trial (36th ESMO 2011), CBDCA + pemetrexed + bevacizumab and its maintenance chemotherapy with pemetrexed + bevacizumab is a new promising regimen for the treatment of advanced non-small-cell lung adenocarcinoma. Herein, we repor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa00db003bb50d39ef4dcda6a78b4f9f
http://europepmc.org/articles/PMC3492973
http://europepmc.org/articles/PMC3492973
Autor:
Kazuyoshi Imaizumi, Joe Shindoh, Hiroyuki Taniguchi, Yoshimasa Tanikawa, Yoshinori Hasegawa, Ryujiro Suzuki, Fumio Nomura, Masashi Yamamoto, Kaoru Shimokata, Hideo Saka, Hideo Gonda
Publikováno v:
Lung Cancer. 63:72-76
Summary Background Cyclooxygenase (COX-2) overexpression is seen in many malignancies including lung cancer. Recent pre-clinical studies have shown that selective COX-2 inhibitors have demonstrated promising results when used with chemotherapy. Based
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f4c688d667df6d5a8f849e6416ca17b
https://doi.org/10.1016/j.lungcan.2008.04.002
https://doi.org/10.1016/j.lungcan.2008.04.002
Autor:
Hideo Gonda
Publikováno v:
Nihon Kikan Shokudoka Gakkai Kaiho. 57:28-34
成人発症の先天性食道気管支瘻の2例を報告する。症例1は65歳，女性。慢性咳嗽の既往歴あり。検診でのバリウム食道造影検査で瘻を指摘されて当院を受診した。胸部CTでは中部食道から
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6649fb8276560f954d82039bb94e5e62
https://doi.org/10.2468/jbes.57.28
https://doi.org/10.2468/jbes.57.28